Ozempic for PCOS: Off-Label Dosing Protocol, Evidence, and Clinical Guidance
HealthRX.com
Ozempic has no FDA-approved dose for PCOS
Key numbers
- 0.25 mgStarting Ozempic dose on the label for type 2 diabetes; the label has no PCOS doseSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 15.8%Nausea rate on 0.5 mg Ozempic in pooled type 2 diabetes trials, versus 6.1% on placeboSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 2 monthsHow long to stop Ozempic before a planned pregnancy, because of the long washout periodSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 12 weeksLength of the PCOS trial comparing liraglutide with metformin in 32 women; no significant weight-loss differenceSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
From the public record
Registered clinical studies of semaglutide and polycystic ovary syndrome
ClinicalTrials.gov lists 6 registered studies that name semaglutide as an intervention and list polycystic ovary syndrome as a condition, as of 2026-11-11. Of these, 2 are recruiting, 1 are completed and 3 are phase 3 studies.
| Measure | Value |
|---|---|
| Registered studies | 6 |
| Recruiting now | 2 |
| Not yet recruiting | 0 |
| Completed | 1 |
| Terminated, withdrawn or suspended | 1 |
| Phase 3 (including phase 2/3) | 3 |
| Phase 2 (including phase 1/2) | 0 |
| Phase 1 | 1 |
How this was calculated
Searched ClinicalTrials.gov for studies naming the drug as an intervention with the stated filter, downloaded every matching record and counted by status and phase. Combined phases are counted under the higher phase.
Studies whose intervention field matches semaglutide and that list polycystic ovary syndrome as a condition, all statuses
A registered study is not a result. Counts include studies where the drug is a comparator or background treatment, and studies that never finished or reported. The filter relies on how each study was registered.
See the public record for Semaglutide
At a glance
- FDA-approved uses / in adults with type 2 diabetes: glycemic control, cardiovascular risk reduction with established cardiovascular disease, and kidney outcomes with chronic kidney disease [1]
- PCOS indication / none [1]
- Starting dose on the label / 0.25 mg once weekly for 4 weeks [1]
- Maintenance doses / 0.5, 1 or 2 mg weekly, each increase after at least 4 weeks at the current dose [1]
- Contraindications / personal or family history of medullary thyroid carcinoma or MEN 2; prior serious hypersensitivity to semaglutide [1]
- Before a planned pregnancy / discontinue at least 2 months before [1]
- Nausea in Ozempic trials / 15.8% at 0.5 mg and 20.3% at 1 mg versus 6.1% on placebo [1]
What Ozempic is approved for
Ozempic (semaglutide injection) was approved on 5 December 2017 [2]. Its label covers three uses, all in adults with type 2 diabetes: improving glycemic control alongside diet and exercise, reducing major adverse cardiovascular events in people with established cardiovascular disease, and reducing the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in people with chronic kidney disease [1]. PCOS is not an approved use, and the Ozempic label has no weight-management indication [1].
What is known about semaglutide in PCOS
PCOS affects an estimated 10 to 13% of reproductive-aged women and is the most common cause of anovulation among women globally [3]. The PCOS trial cited here studied liraglutide, not semaglutide. It found no significant difference in weight loss between liraglutide 1.2 mg daily and metformin 1,000 mg twice daily over 12 weeks in 32 women with obesity and newly diagnosed PCOS [4].
Semaglutide weight data come from a different population. STEP 1 enrolled 1,961 adults with a BMI of 30 or more (or 27 or more with a weight-related condition) and no diabetes. They lost a mean 14.9% of body weight on 2.4 mg weekly over 68 weeks versus 2.4% on placebo [5]. The 2.4 mg dose in that trial is the Wegovy dose; the Ozempic label maximum is 2 mg weekly [1].
The label's dosing schedule
For its approved uses, the Ozempic label starts at 0.25 mg once weekly for 4 weeks, then 0.5 mg. If more glycemic control is needed, it allows 1 mg after at least 4 weeks on 0.5 mg, and 2 mg after at least 4 weeks on 1 mg, with a 2 mg weekly maximum [1]. It is injected subcutaneously once weekly, on the same day each week, at any time of day, with or without meals [1]. The label says a missed dose can be given within 5 days; after that the dose is skipped [1].
Questions worth asking
What the label says to watch for
The boxed warning covers thyroid C-cell tumors seen in rodents at clinically relevant exposures; whether semaglutide causes them in humans, including medullary thyroid carcinoma, is unknown [1]. Ozempic is contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2, and after a serious hypersensitivity reaction to semaglutide or an excipient [1]. In pooled placebo-controlled type 2 diabetes trials (262 on placebo, 260 on 0.5 mg, 261 on 1 mg), nausea occurred in 6.1%, 15.8% and 20.3%, and 0.4%, 3.1% and 3.8% stopped treatment for gastrointestinal reasons [1]. The label also warns about acute pancreatitis, acute gallbladder disease, hypoglycemia with insulin or an insulin secretagogue, acute kidney injury from volume depletion and pulmonary aspiration during anesthesia or deep sedation, and says the drug is not recommended in severe gastroparesis [1].
What people on Reddit report
Reddit accounts from r/PCOS users who took semaglutide (Ozempic) and described side effects, starting doses and how they managed them.
I had some side effects around week 6, mostly acid reflux and constipation but it responded well to omeprazole (otc) and magnesium (an oral supplement). It completely went away after that.Read the source discussion
I didn't have any side effects apart from the third month in when I felt a bit sick going up a dose. You must always start at the lowest dose otherwise youll get sick.Read the source discussion
I would recommend to anyone starting: drink a buttload of water and take psyllium husk capsules to keep the digestion moving.Read the source discussion
I will add to be very very careful with your iron, protein and vitamin intake. My appetite disappeared even at the lowest dose of ozempic and I lost half my hair by the end of those 5 months.Read the source discussion
Metformin never worked for me and I tried ozempic and felt so sick.Read the source discussion
Pregnancy and compounded products
The Ozempic label reports limited human pregnancy data and animal studies showing embryofetal mortality and structural abnormalities, and says to discontinue at least 2 months before a planned pregnancy because of the long washout period [1]. FDA says compounded semaglutide is not FDA approved and is not reviewed for safety, effectiveness or quality before marketing [7].
Check what you know
Question 1 of 5
Score: 0 right, 0 of 5 answered
Frequently asked questions
Is Ozempic FDA-approved for PCOS?
What dose of Ozempic is used for PCOS?
What PCOS trial data exist for GLP-1 drugs?
What are the common side effects of Ozempic?
Can semaglutide be used during pregnancy?
Reader questions
What people actually ask
Short answers drawn from the sources this article cites.
Does Ozempic help if you have PCOS?
Not established. Ozempic is not FDA-approved for PCOS, and the only PCOS trial cited studied liraglutide, not semaglutide. That trial found no significant difference in weight loss between liraglutide and metformin over 12 weeks in 32 women with obesity and newly diagnosed PCOS.
Is 2 mg of Ozempic too much to start with?
No, 2 mg is not a starting dose. It is the label maximum weekly dose, reached only after at least 4 weeks on 1 mg. The label schedule begins at 0.25 mg once weekly for 4 weeks.
References
Show all 9 referencesHide references
- U.S. National Library of Medicine, DailyMed. Ozempic injection (Novo Nordisk) prescribing information. Ozempic injection (Novo Nordisk) label
- Drugs@FDA: FDA-Approved Drugs.
- Polycystic ovary syndrome.
- Jensterle M, Kravos NA, Pfeifer M, Kocjan T, Janez A. A 12-week treatment with the long-acting glucagon-like peptide 1 receptor agonist liraglutide leads to significant weight loss in a subset of obese women with newly diagnosed polycystic ovary syndrome. Hormones (Athens). 2015;14(1):81-90.
- Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002.
- FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize | FDA.
- FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss | FDA.
- Reddit participants. Ozempic for PCOS (r/PCOS). Accessed 2026-11-11.
- Reddit participants. Do I even bother with ozempic? (r/PCOS). Accessed 2026-11-11.